9-ING-41 [1034895-42-5]

MedChem Express

9-ING-41 [1034895-42-5]

9

1034895-42-5

Research Use Only

99.13

C22H13FN2O5

404.35

9-ING-41 (Elraglusib) is a maleimide-based ATP-competitive and selective glycogen synthase kinase-3beta (GSK-3beta) inhibitor with an IC50 of 0.71 microM. 9-ING-41 significantly leads to cell cycle arrest, autophagy and apoptosis in cancer cells. 9-ING-41 has anticancer activity and has the potential for enhancing the antitumor effects of chemotherapeutic agents[1][2][3][4].

O=C(C(C1=COC2=CC=C(F)C=C12)=C3C4=CN(C)C5=C4C=C6C(OCO6)=C5)NC3=O

-20°C,2°C to 8°C

12352200